ANIX (Anixa Biosciences) סך כל נכסי החברה

Anixa Biosciences, Inc. (ANIX) is developing innovative early tumor detection systems, leveraging its patent portfolio to capitalize on expertise in women's healthcare. High costs associated with FDA certification and clinical trials for breast cancer vaccines create a significant barrier to entry for competitors. The business strategy relies on a balance between oncological and antiviral developments. This chart of the asset's value on GURU.Markets shows that the total resources amount to 16.36.

Anixa Biosciences, Inc. (ANIX) expansion into the women's oncology sector requires significant resource allocation for vaccine development. This metric, calculated inversely via ROA, aggregates equity and liabilities, reflecting the total value of controlled assets. The growth of this value confirms the expansion of the material base necessary for scaling biotechnological projects. By analyzing total asset dynamics, an investor can assess the efficiency of resource accumulation and the risks of redundancy.